Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Imaging Neuroinflammation in Neurodegenerative Disorders

Joseph C. Masdeu, Belen Pascual and Masahiro Fujita
Journal of Nuclear Medicine June 2022, 63 (Supplement 1) 45S-52S; DOI: https://doi.org/10.2967/jnumed.121.263200
Joseph C. Masdeu
1Nantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belen Pascual
1Nantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Fujita
1Nantz National Alzheimer Center, Stanley H. Appel Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas; and
2PET Core, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Translocator protein 18 kDa (TSPO) PET in AD. Inflammation imaging at presymptomatic, MCI, and dementia stages of AD process. In each subject, multimodal imaging is shown, to illustrate spatial correlation of inflammation, in bottom row of every individual scan, with amyloid and tau imaging. CDR = clinical dementia rating scale; HAB = TSPO-high-affinity binder subject; MAB = TSPO-mixed-affinity binder subject; SUVR = standardized uptake value ratio; VT = volume of distribution.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    TSPO PET in FTD. Inflammation imaging in behavioral variant of FTD and in the nonfluent and semantic variants of primary progressive aphasia (PPA), also categorized as FTD. Amyloid PET was negative in all subjects. In semantic variant PPA, peak of inflammation is at periphery of most affected area, which has atrophy on MRI. HAB = TSPO-high-affinity binder subject; MAB = TSPO-mixed-affinity binder subject; SUVR = standardized uptake value ratio; VT = volume of distribution. (Lower 2 panels are adapted with permission of (71)).

Additional Files

  • Figures
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (Supplement 1)
Journal of Nuclear Medicine
Vol. 63, Issue Supplement 1
June 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging Neuroinflammation in Neurodegenerative Disorders
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Imaging Neuroinflammation in Neurodegenerative Disorders
Joseph C. Masdeu, Belen Pascual, Masahiro Fujita
Journal of Nuclear Medicine Jun 2022, 63 (Supplement 1) 45S-52S; DOI: 10.2967/jnumed.121.263200

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging Neuroinflammation in Neurodegenerative Disorders
Joseph C. Masdeu, Belen Pascual, Masahiro Fujita
Journal of Nuclear Medicine Jun 2022, 63 (Supplement 1) 45S-52S; DOI: 10.2967/jnumed.121.263200
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • TSPO PET: CURRENT TARGET TO IMAGE NEUROINFLAMMATION
    • NEUROINFLAMMATION PET IN NEURODEGENERATIVE DISORDERS
    • LIMITATIONS OF TSPO PET
    • NEW INFLAMMATION IMAGING TARGETS TO OVERCOME THE LIMITATIONS OF TSPO PET
    • OTHER PET MARKERS TO STUDY NEUROINFLAMMATION
    • LINKAGE BETWEEN PERIPHERAL AND CENTRAL INFLAMMATION
    • DISCLOSURE
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Progressive lifespan modifications in the corpus callosum following a single juvenile concussion in male mice monitored by diffusion MRI
  • Molecular Imaging of Neurodegeneration: The Way to New Horizons
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

Keywords

  • Molecular imaging
  • Neurology
  • PET
  • Alzheimer’s disease
  • neurodegeneration
  • neuroinflammation
  • Positron Emission Tomography
  • TSPO
SNMMI

© 2025 SNMMI

Powered by HighWire